Author/Authors :
Kazuo Yamada، نويسنده , , Tetsuo Ohnishi، نويسنده , , Kenji Hashimoto، نويسنده , , Hisako Ohba، نويسنده , , Yoshimi Iwayama-Shigeno، نويسنده , , Manabu Toyoshima، نويسنده , , Akira Okuno، نويسنده , , Hitomi Takao، نويسنده , , Tomoko Toyota، نويسنده , , Yoshio Minabe، نويسنده , , Kazuhiko Nakamura، نويسنده , , Eiji Shimizu، نويسنده , , Masanari Itokawa، نويسنده , , Norio Mori، نويسنده , , Masaomi Iyo
، نويسنده , , Takeo Yoshikawa، نويسنده ,
Abstract :
Background
We previously reported a reduction in serum levels of d-serine, an endogenous co-agonist of the N-methyl-D-aspartate (NMDA) receptor, in schizophrenia, supporting the hypofunction hypothesis of NMDA neurotransmission in schizophrenia. In this study, we examined the genetic roles of serine racemase (SRR), an enzyme catalyzing the formation of d-serine from l-serine, and d-amino-acid oxidase (DAO) in the susceptibility to schizophrenia and the regulation of serum d-serine levels.
Methods
We determined the complete cDNA and genomic structures of SRR and performed mutation screening. Single nucleotide polymorphisms (SNPs) in SRR and DAO were tested for their association with schizophrenia in both case-control and family-based designs and for correlation with serum levels of d-serine.
Results
Genomic analyses revealed that human brain SRR transcripts consist of four isoforms with one major species, which were derived from alternative use of various 5’ end exons. Genetic association analyses showed no significant association between SRR/DAO and schizophrenia. We replicated the decreased serum d-serine levels in schizophrenia in the sample set, but d-serine levels did not correlate with SRR/DAO genotypes.
Conclusions
The SRR/DAO are not likely to be major genetic determinants in the development of schizophrenia or control of serum d-serine levels.
Keywords :
N-methyl-D-aspartate receptor , Genotype–phenotype correlation , Alternative splicing , Mutation screening , glycine site , polymorphism.